Target Price | CHF28.97 |
Price | CHF16.84 |
Potential |
72.03%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target PolyPeptide 2026 .
The average PolyPeptide target price is CHF28.97.
This is
72.03%
register free of charge
CHF44.56
164.60%
register free of charge
CHF18.82
11.74%
register free of charge
|
|
A rating was issued by 6 analysts: 3 Analysts recommend PolyPeptide to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the PolyPeptide stock has an average upside potential 2026 of
72.03%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million CHF | 320.83 | 385.97 |
3.07% | 20.30% | |
EBITDA Margin | 6.94% | 13.48% |
312.14% | 94.29% | |
Net Margin | -5.86% | 1.20% |
63.62% | 120.47% |
5 Analysts have issued a sales forecast PolyPeptide 2025 . The average PolyPeptide sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an PolyPeptide EBITDA forecast 2025. The average PolyPeptide EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 PolyPeptide Analysts have issued a net profit forecast 2025. The average PolyPeptide net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | -0.57 | 0.14 |
62.50% | 124.56% | |
P/E | 119.49 | |
EV/Sales | 1.50 |
3 Analysts have issued a PolyPeptide forecast for earnings per share. The average PolyPeptide EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.